Sabine D. Brookman-May, Professor of Urology at Universität München, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post by European Urology on X:
“Data from our phase 1 study with AU-011/Bel-Sar, a Virus-Drug-Conjugate (VDC), in NIMBC presented by Seth Lerner SIU23.
Immune response and preliminary efficacy of bel-sar (AU-011), a first-in-class virus-like drug conjugate (VDC), in patients with NMIBC
- In IR and HR NMIBC patients, focal administration of a single, low-dose of bel-sar induced complete responses in injected and non-injected tumors through rapid tumor necrosis, effector cell infiltration, localized immune memory, and a urothelial field effect
- Bel-sar induced adaptive immune memory with generation of de novo mature TLS
- Generation of innate and adaptive effectors regardless of immune environment + conversion of cold to hot tumors + reversed dysfunction in exhausted tumors
- Grade 1 drug-related adverse events only Great basis to further evaluate AU-011’s clinical efficacy with higher doses and repeat cycles + in immune-ablative and neo-adjuvant treatment paradigms in the ongoing phase 1b/2 study.”
More posts featuring Sabine D. Brookman-May on OncoDaily.
